MedTrace Logo

Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

NCT01755182 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-05-06

No results posted yet for this study

Summary

The purpose of this study is to verify if adding a locoregional treatment of liver metastasis (with trans-arterial embolization-TAE) to medical treatments of proven efficacy can prolong the progression free survival of patients affected by neuroendocrine tumors (NET) with inoperable liver metastases

Conditions

Interventions

DRUG

approved pharmacologic therapy

PROCEDURE

TAE

after randomization, and after 3 months

Sponsors & Collaborators

  • Federico II University

    collaborator OTHER

  • University of Campania Luigi Vanvitelli

    collaborator OTHER

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • A Colao, M.D. · Federico II University

  • A Faggiano, M.D. · Federico II University

  • R D'Angelo, M.D. · NCI Naples

  • F Fiore, MD · NCI Naples

  • F Perrone, MD · NCI Naples

  • C Gallo, MD · University of Campania Luigi Vanvitelli

  • MC Piccirillo, MD · NCI Naples

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01755182 on ClinicalTrials.gov